Vesper Fe Marie Llaneza Ramos
Research Subjects
Research Interests
Vesper Fe Marie Llaneza Ramos has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Mark Hallett
Human Motor Control Section, National Institutes of Health, Bethesda, USA
6 shared publications Codrin Lungu
5 shared publicationsKatharine Alter
4 shared publicationsMark Hallett
Human Motor Control Section National Institutes of Health Bethesda Maryland USA
4 shared publicationsBarbara I. Karp
CNS IRB National Institutes of Health Bethesda Maryland USA
2 shared publications- Barbara Illowsky Karp
National Institute of Neurological Disorders and Stroke, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD, 20892, USA
2 shared publications
Latest Publications
- Open Access
- 21 October 2020
- Published by JMIR Publications Inc. in JMIR Rehabilitation and Assistive Technologies
- Vol. 7 (2) , e17986
The Impact of Reducing the Number of Wearable Devices on Measuring Gait in Parkinson Disease: Noninterventional Exploratory Study
Background: Measuring free-living gait using wearable devices may offer higher granularity and temporal resolution than the current clinical assessments for patients with Parkinson disease (PD). However, increasing the number of devices worn on the body adds to the patient burden and impacts the compliance. Objective: This study aimed to investigate the impact of reducing the number of wearable devices on the ability to assess gait impairments in patients with PD. Methods: A total of 35 volunteers with PD and 60 healthy volunteers performed a gait task during 2 clinic visits. Participants with PD were assessed in the On and Off medication state using the Movement Disorder Society version of the Unified Parkinson Disease Rating Scale (MDS-UPDRS). Gait features derived from a single lumbar-mounted accelerometer were compared with those derived using 3 and 6 wearable devices for both participants with PD and healthy participants. Results: A comparable performance was observed for predicting the MDS-UPDRS gait score using longitudinal mixed-effects model fit with gait features derived from a single (root mean square error [RMSE]=0.64; R2=0.53), 3 (RMSE=0.64; R2=0.54), and 6 devices (RMSE=0.54; R2=0.65). In addition, MDS-UPDRS gait scores predicted using all 3 models differed significantly between On and Off motor states (single device, P=.004; 3 devices, P=.004; 6 devices, P=.045). Conclusions: We observed a marginal benefit in using multiple devices for assessing gait impairments in patients with PD when compared with gait features derived using a single lumbar-mounted accelerometer. The wearability burden associated with the use of multiple devices may offset gains in accuracy for monitoring gait under free-living conditions.
- 21 October 2020
- Published by JMIR Publications Inc. in JMIR Rehabilitation and Assistive Technologies
- Vol. 7 (2) , e17986
Open AccessThe Impact of Reducing the Number of Wearable Devices on Measuring Gait in Parkinson Disease: Noninterventional Exploratory Study
Background: Measuring free-living gait using wearable devices may offer higher granularity and temporal resolution than the current clinical assessments for patients with Parkinson disease (PD). However, increasing the number of devices worn on the body adds to the patient burden and impacts the compliance. Objective: This study aimed to investigate the impact of reducing the number of wearable devices on the ability to assess gait impairments in patients with PD. Methods: A total of 35 volunteers with PD and 60 healthy volunteers performed a gait task during 2 clinic visits. Participants with PD were assessed in the On and Off medication state using the Movement Disorder Society version of the Unified Parkinson Disease Rating Scale (MDS-UPDRS). Gait features derived from a single lumbar-mounted accelerometer were compared with those derived using 3 and 6 wearable devices for both participants with PD and healthy participants. Results: A comparable performance was observed for predicting the MDS-UPDRS gait score using longitudinal mixed-effects model fit with gait features derived from a single (root mean square error [RMSE]=0.64; R2=0.53), 3 (RMSE=0.64; R2=0.54), and 6 devices (RMSE=0.54; R2=0.65). In addition, MDS-UPDRS gait scores predicted using all 3 models differed significantly between On and Off motor states (single device, P=.004; 3 devices, P=.004; 6 devices, P=.045). Conclusions: We observed a marginal benefit in using multiple devices for assessing gait impairments in patients with PD when compared with gait features derived using a single lumbar-mounted accelerometer. The wearability burden associated with the use of multiple devices may offset gains in accuracy for monitoring gait under free-living conditions.
- Open Access
- 27 January 2020
- Published by JMIR Publications Inc. in JMIR Preprints
The Impact of Reducing the Number of Wearable Devices on Measuring Gait in Parkinson Disease: Noninterventional Exploratory Study (Preprint)
BACKGROUND Measuring free-living gait using wearable devices may offer higher granularity and temporal resolution than the current clinical assessments for patients with Parkinson disease (PD). However, increasing the number of devices worn on the body adds to the patient burden and impacts the compliance. OBJECTIVE This study aimed to investigate the impact of reducing the number of wearable devices on the ability to assess gait impairments in patients with PD. METHODS A total of 35 volunteers with PD and 60 healthy volunteers performed a gait task during 2 clinic visits. Participants with PD were assessed in the On and Off medication state using the Movement Disorder Society version of the Unified Parkinson Disease Rating Scale (MDS-UPDRS). Gait features derived from a single lumbar-mounted accelerometer were compared with those derived using 3 and 6 wearable devices for both participants with PD and healthy participants. RESULTS A comparable performance was observed for predicting the MDS-UPDRS gait score using longitudinal mixed-effects model fit with gait features derived from a single (root mean square error [RMSE]=0.64; R2=0.53), 3 (RMSE=0.64; R2=0.54), and 6 devices (RMSE=0.54; R2=0.65). In addition, MDS-UPDRS gait scores predicted using all 3 models differed significantly between On and Off motor states (single device, P=.004; 3 devices, P=.004; 6 devices, P=.045). CONCLUSIONS We observed a marginal benefit in using multiple devices for assessing gait impairments in patients with PD when compared with gait features derived using a single lumbar-mounted accelerometer. The wearability burden associated with the use of multiple devices may offset gains in accuracy for monitoring gait under free-living conditions. CLINICALTRIAL
- 27 January 2020
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessThe Impact of Reducing the Number of Wearable Devices on Measuring Gait in Parkinson Disease: Noninterventional Exploratory Study (Preprint)
BACKGROUND Measuring free-living gait using wearable devices may offer higher granularity and temporal resolution than the current clinical assessments for patients with Parkinson disease (PD). However, increasing the number of devices worn on the body adds to the patient burden and impacts the compliance. OBJECTIVE This study aimed to investigate the impact of reducing the number of wearable devices on the ability to assess gait impairments in patients with PD. METHODS A total of 35 volunteers with PD and 60 healthy volunteers performed a gait task during 2 clinic visits. Participants with PD were assessed in the On and Off medication state using the Movement Disorder Society version of the Unified Parkinson Disease Rating Scale (MDS-UPDRS). Gait features derived from a single lumbar-mounted accelerometer were compared with those derived using 3 and 6 wearable devices for both participants with PD and healthy participants. RESULTS A comparable performance was observed for predicting the MDS-UPDRS gait score using longitudinal mixed-effects model fit with gait features derived from a single (root mean square error [RMSE]=0.64; R2=0.53), 3 (RMSE=0.64; R2=0.54), and 6 devices (RMSE=0.54; R2=0.65). In addition, MDS-UPDRS gait scores predicted using all 3 models differed significantly between On and Off motor states (single device, P=.004; 3 devices, P=.004; 6 devices, P=.045). CONCLUSIONS We observed a marginal benefit in using multiple devices for assessing gait impairments in patients with PD when compared with gait features derived using a single lumbar-mounted accelerometer. The wearability burden associated with the use of multiple devices may offset gains in accuracy for monitoring gait under free-living conditions. CLINICALTRIAL
- Open Access
- 1 January 2017
- Published by Open Access Text Pvt, Ltd. in Clinical Research and Trials
- Vol. 3 (3)
Botulinum toxin injection following deep brain stimulation in generalized dystonia
- 1 January 2017
- Published by Open Access Text Pvt, Ltd. in Clinical Research and Trials
- Vol. 3 (3)
Open AccessBotulinum toxin injection following deep brain stimulation in generalized dystonia
- 1 July 2016
- Published by Elsevier in Neurobiology of Aging
- Vol. 43, 174-179
Temporal discrimination threshold with healthy aging
- 1 July 2016
- Published by Elsevier in Neurobiology of Aging
- Vol. 43, 174-179
Temporal discrimination threshold with healthy aging
- 10 February 2016
- Published by H1 Connect
- Vol. 26 (2)
Faculty Opinions recommendation of Supine hypertension in Parkinson's disease and multiple system atrophy.
Increased supine hypertension (SH) is associated with antihypertensive medication use in multiple systems atrophy (MSA) patients and cardiovascular comorbidities in Parkinson's disease (PD) patients. SH is elevated blood pressure when lying down. It is a controversial entity, with respect to etiology and treatment. Fanciulli et al. studied a retrospective cohort of 197 patients with PD and 78 patients with MSA to investigate...
- 10 February 2016
- Published by H1 Connect
- Vol. 26 (2)
Faculty Opinions recommendation of Supine hypertension in Parkinson's disease and multiple system atrophy.
Increased supine hypertension (SH) is associated with antihypertensive medication use in multiple systems atrophy (MSA) patients and cardiovascular comorbidities in Parkinson's disease (PD) patients. SH is elevated blood pressure when lying down. It is a controversial entity, with respect to etiology and treatment. Fanciulli et al. studied a retrospective cohort of 197 patients with PD and 78 patients with MSA to investigate...
- Open Access
- 9 January 2016
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 3 (3) , 282-284
Ultrasound as Diagnostic Tool for Diaphragmatic Myoclonus
Background: Diaphragmatic myoclonus is a rare disorder of repetitive diaphragmatic contractions, acknowledged to be a spectrum that includes psychogenic features. Electromyography has been the diagnostic tool most commonly used in the literature. Methods: To test whether we could perform a noninvasive technique to delineate the diaphragm as the source of abnormal movements and demonstrate distractibility and entrainability, we used B‐mode ultrasound in a patient with diaphragmatic myoclonus. Results: Ultrasound imaging clearly delineated the diaphragm as the source of her abdominal movements. We were able to demonstrate entrainability of the diaphragm to hand tapping to a prescribed rhythm set by the examiner. Conclusions: We recommend the use of ultrasound as a noninvasive, convenient diagnostic tool for further studies of diaphragmatic myoclonus. We agree with previous findings that diaphragmatic myoclonus may be a functional movement disorder, as evidenced by distractibility and entrainability demonstrated on real‐time video with ultrasonography.
- 9 January 2016
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 3 (3) , 282-284
Open AccessUltrasound as Diagnostic Tool for Diaphragmatic Myoclonus
Background: Diaphragmatic myoclonus is a rare disorder of repetitive diaphragmatic contractions, acknowledged to be a spectrum that includes psychogenic features. Electromyography has been the diagnostic tool most commonly used in the literature. Methods: To test whether we could perform a noninvasive technique to delineate the diaphragm as the source of abnormal movements and demonstrate distractibility and entrainability, we used B‐mode ultrasound in a patient with diaphragmatic myoclonus. Results: Ultrasound imaging clearly delineated the diaphragm as the source of her abdominal movements. We were able to demonstrate entrainability of the diaphragm to hand tapping to a prescribed rhythm set by the examiner. Conclusions: We recommend the use of ultrasound as a noninvasive, convenient diagnostic tool for further studies of diaphragmatic myoclonus. We agree with previous findings that diaphragmatic myoclonus may be a functional movement disorder, as evidenced by distractibility and entrainability demonstrated on real‐time video with ultrasonography.
- 16 October 2015
- Published by H1 Connect
- Vol. 14 (10)
Faculty Opinions recommendation of Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study.
Nalls et al. utilized population-based modelling, with the data from the Parkinson's Progression Marker Initiative study of 367 patients and 165 controls, to develop an algorithm to differentiate patients with Parkinson's disease from healthy volunteers with 83% sensitivity and 90% specificity. Their model had five components selected by step-wise logistic regression: hyposmia based on the University of Pennsylvania Smell Identification...
- 16 October 2015
- Published by H1 Connect
- Vol. 14 (10)
Faculty Opinions recommendation of Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study.
Nalls et al. utilized population-based modelling, with the data from the Parkinson's Progression Marker Initiative study of 367 patients and 165 controls, to develop an algorithm to differentiate patients with Parkinson's disease from healthy volunteers with 83% sensitivity and 90% specificity. Their model had five components selected by step-wise logistic regression: hyposmia based on the University of Pennsylvania Smell Identification...
- 3 June 2015
- Published by H1 Connect
Faculty Opinions recommendation of Parkinson's disease and narcolepsy-like symptoms.
Linking Parkinson's Disease and Narcolepsy. To assess the occurrence of sleep attacks, cataplexy, rapid eye movement (REM) behavior disorder, and hallucinations in Parkinson’s disease in general, Ylikoski et al. utilized a 207-item structured questionnaire with the Epworth Sleepiness Scale and the Ullanlinna Narcolepsy Scale. They had a 59% responder rate (N=854), with 623 Parkinson’s disease patients completing the questionnaires. They found, somewhat surprisingly, that 11% had narcolepsy-like symptoms, with suspected narcolepsy in 9.3%, much higher than general population prevalence rates for narcolepsy (0.026%) {1,2}. Some years ago, there was first notice of the sleep attacks in Parkinson’s disease patients possibly related to dopamine agonist therapy {3}. This study brings a spotlight on a possible link between Parkinson’s disease and narcolepsy itself, which is quite plausible given the shared symptomatology (excessive daytime somnolence, hypnagogic/hypnopompic hallucinations, sleep attacks, REM sleep behavior disorder, cataplexy, and motor paralysis [‘sleep’ paralysis]), associated hypocretin deficiency, and similar treatments such as modafinil and selegiline. It is interesting that dopamine-releasing medications such as amphetamines and dopamine-reuptake inhibitors such as methylphenidate are useful in narcolepsy. A crucial difference, of course, is that Parkinson’s disease is neurodegenerative, while narcolepsy per se is not known to be progressive. The authors hypothesize symptoms of narcolepsy in Parkinson’s disease are probably secondary to the Parkinson’s disease but also consider that patients with narcolepsy and cataplexy may be at risk for developing Parkinson’s disease. An earlier retrospective chart review suggests this second hypothesis and proposes that amphetamine treatment related to narcolepsy may be the link to the two {4}. Another question to explore is how much of the signs and symptoms impairing quality of life for Parkinson’s disease patients may be helped by treating narcolepsy or promoting good sleep? Further exploration of this link might be important to both disease entities, in terms of understanding pathogenesis and developing treatments. Future studies should involve multiple sleep latency tests and/or polysomnography.
- 3 June 2015
- Published by H1 Connect
Faculty Opinions recommendation of Parkinson's disease and narcolepsy-like symptoms.
Linking Parkinson's Disease and Narcolepsy. To assess the occurrence of sleep attacks, cataplexy, rapid eye movement (REM) behavior disorder, and hallucinations in Parkinson’s disease in general, Ylikoski et al. utilized a 207-item structured questionnaire with the Epworth Sleepiness Scale and the Ullanlinna Narcolepsy Scale. They had a 59% responder rate (N=854), with 623 Parkinson’s disease patients completing the questionnaires. They found, somewhat surprisingly, that 11% had narcolepsy-like symptoms, with suspected narcolepsy in 9.3%, much higher than general population prevalence rates for narcolepsy (0.026%) {1,2}. Some years ago, there was first notice of the sleep attacks in Parkinson’s disease patients possibly related to dopamine agonist therapy {3}. This study brings a spotlight on a possible link between Parkinson’s disease and narcolepsy itself, which is quite plausible given the shared symptomatology (excessive daytime somnolence, hypnagogic/hypnopompic hallucinations, sleep attacks, REM sleep behavior disorder, cataplexy, and motor paralysis [‘sleep’ paralysis]), associated hypocretin deficiency, and similar treatments such as modafinil and selegiline. It is interesting that dopamine-releasing medications such as amphetamines and dopamine-reuptake inhibitors such as methylphenidate are useful in narcolepsy. A crucial difference, of course, is that Parkinson’s disease is neurodegenerative, while narcolepsy per se is not known to be progressive. The authors hypothesize symptoms of narcolepsy in Parkinson’s disease are probably secondary to the Parkinson’s disease but also consider that patients with narcolepsy and cataplexy may be at risk for developing Parkinson’s disease. An earlier retrospective chart review suggests this second hypothesis and proposes that amphetamine treatment related to narcolepsy may be the link to the two {4}. Another question to explore is how much of the signs and symptoms impairing quality of life for Parkinson’s disease patients may be helped by treating narcolepsy or promoting good sleep? Further exploration of this link might be important to both disease entities, in terms of understanding pathogenesis and developing treatments. Future studies should involve multiple sleep latency tests and/or polysomnography.
- Open Access
- 17 April 2015
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 2 (6) , 707-710
Intraoperative neurophysiology in deep brain surgery for psychogenic dystonia
Psychogenic dystonia is a challenging entity to diagnose and treat because little is known about its pathophysiology. We describe two cases of psychogenic dystonia who underwent deep brain stimulation when thought to have organic dystonia. The intraoperative microelectrode recordings in globus pallidus internus were retrospectively compared with those of five patients with known DYT1 dystonia using spontaneous discharge parameters of rate and bursting, as well as movement-related discharges. Our data suggest that simple intraoperative neurophysiology measures in single subjects do not differentiate psychogenic dystonia from DYT1 dystonia.
- 17 April 2015
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 2 (6) , 707-710
Open AccessIntraoperative neurophysiology in deep brain surgery for psychogenic dystonia
Psychogenic dystonia is a challenging entity to diagnose and treat because little is known about its pathophysiology. We describe two cases of psychogenic dystonia who underwent deep brain stimulation when thought to have organic dystonia. The intraoperative microelectrode recordings in globus pallidus internus were retrospectively compared with those of five patients with known DYT1 dystonia using spontaneous discharge parameters of rate and bursting, as well as movement-related discharges. Our data suggest that simple intraoperative neurophysiology measures in single subjects do not differentiate psychogenic dystonia from DYT1 dystonia.
- 9 March 2015
- Published by H1 Connect
Faculty Opinions recommendation of Placebo effect of medication cost in Parkinson disease: a randomized double-blind study.
The placebo effect is well-known in Parkinson's disease. Twelve patients with moderate to severe Parkinson's disease were given placebo normal saline injections in a 'prospective double blind cross over' design. Participants were told that they would be allocated to a 'cheap' first group (cost 100USD) or an 'expensive' first group (cost 1500USD). They underwent motor assessments and functional magnetic resonance imaging (fMRI) then switched 4 hours later, and underwent the same studies. The investigators found about 10% greater improvement in motor function with expensive placebo as compared with cheap placebo. Brain activation with the fMRI task was greater in the 'cheap' first group. Only cheap placebo increased activation "in the left lateral sensorimotor cortex and other regions". The conclusion was that perceptions of cost alter the placebo response, with more expensive placebos improving motor function more than cheap placebos, and that the differences were associated with brain activation changes. Expectation has an influence on response and generally, people have the idea that the more expensive something is, the better it will be {1}. In another area of investigation, it has often been found that people like a wine more if it is said to be more expensive {2}. This study extends this result to the value of placebos. The study itself raises concerns. First, the method included intentional deception. The study was even allowed to not be registered as a clinical trial "to prevent disclosure of the true nature of the study to any prospective participants." As the study is "no more than minimal risk", such deception can be approved by an Institutional Review Board. Second, in some sense, the study is not actually double-blinded. The subjects were, in fact, intentionally given expectations, when blinding is ordinarily done to prevent bias. In this case though, expectations were themselves being investigated. Third, though Espay et al. appear to prove that cost gives an intrinsic bias, cost is a complex parameter. 'Cheap' and 'expensive' are subjective depending on an individual's background, beliefs, and financial status. Patients with Parkinson's disease are particularly prone to placebo effects, and this result might not be generalizable to other patient groups. It would have been interesting to study the responses of debriefing the study participants. Espay et al. succeed in showing that Parkinsonian patients' response to treatments can be manipulated by information from treating physicians, and is likely a general truth worth keeping in mind.
- 9 March 2015
- Published by H1 Connect
Faculty Opinions recommendation of Placebo effect of medication cost in Parkinson disease: a randomized double-blind study.
The placebo effect is well-known in Parkinson's disease. Twelve patients with moderate to severe Parkinson's disease were given placebo normal saline injections in a 'prospective double blind cross over' design. Participants were told that they would be allocated to a 'cheap' first group (cost 100USD) or an 'expensive' first group (cost 1500USD). They underwent motor assessments and functional magnetic resonance imaging (fMRI) then switched 4 hours later, and underwent the same studies. The investigators found about 10% greater improvement in motor function with expensive placebo as compared with cheap placebo. Brain activation with the fMRI task was greater in the 'cheap' first group. Only cheap placebo increased activation "in the left lateral sensorimotor cortex and other regions". The conclusion was that perceptions of cost alter the placebo response, with more expensive placebos improving motor function more than cheap placebos, and that the differences were associated with brain activation changes. Expectation has an influence on response and generally, people have the idea that the more expensive something is, the better it will be {1}. In another area of investigation, it has often been found that people like a wine more if it is said to be more expensive {2}. This study extends this result to the value of placebos. The study itself raises concerns. First, the method included intentional deception. The study was even allowed to not be registered as a clinical trial "to prevent disclosure of the true nature of the study to any prospective participants." As the study is "no more than minimal risk", such deception can be approved by an Institutional Review Board. Second, in some sense, the study is not actually double-blinded. The subjects were, in fact, intentionally given expectations, when blinding is ordinarily done to prevent bias. In this case though, expectations were themselves being investigated. Third, though Espay et al. appear to prove that cost gives an intrinsic bias, cost is a complex parameter. 'Cheap' and 'expensive' are subjective depending on an individual's background, beliefs, and financial status. Patients with Parkinson's disease are particularly prone to placebo effects, and this result might not be generalizable to other patient groups. It would have been interesting to study the responses of debriefing the study participants. Espay et al. succeed in showing that Parkinsonian patients' response to treatments can be manipulated by information from treating physicians, and is likely a general truth worth keeping in mind.